Tech Company Financing Transactions
PaxVax Funding Round
On 7/28/2014, PaxVax raised $62 million in Series B funding from Blue Haven Initiative, Ignition Capital and Pharmakon Advisors.
Transaction Overview
Company Name
Announced On
7/28/2014
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$62,000,000
Round
Series B
Investors
Proceeds Purpose
This financing was secured as part of the company's acquisition of the FDA-approved oral typhoid vaccine Vivotif® from Crucell Switzerland AG. Additional proceeds will be used to support clinical development, regulatory review and the expected global launch of PaxVax's cholera vaccine candidate, PXVX0200, currently in Phase 3 clinical testing.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
555 Twin Dolphin Dr. 360
Redwood City, CA 94065
USA
Redwood City, CA 94065
USA
Phone
Website
Email Address
Overview
PaxVax is initially focused on delivering vaccines for the travelers markets. An estimated 100 million people (families, students, workers and soldiers) per year travel to developing countries where tropical diseases are endemic and vaccines are needed for protection.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Nima Farzan
Chief Financial Officer
Philip Moody
Chief Medical Officer
Lisa Danzig
Chief Scientific Officer
Jonathan Smith
VP - Bus. Development
Mark Meltz
VP - Human Resources
Britt Huber
VP - Operations
Kurt Reichen
VP - Regulatory Affairs
Marc Gurwith
Browse more venture capital transactions:
Prev: 7/28/2014: Quantenna Communications venture capital transaction
Next: 7/28/2014: Bright Computing venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs